HomeCompareEES vs ABBV

EES vs ABBV: Dividend Comparison 2026

EES yields 1.23% · ABBV yields 3.67%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $18.5K in total portfolio value
10 years
EES
EES
● Live price
1.23%
Share price
$57.99
Annual div
$0.71
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21.4K
Annual income
$133.51
Full EES calculator →
ABBV
AbbVie Inc.
● Live price
3.67%
Share price
$168.90
Annual div
$6.20
5Y div CAGR
8.9%
Payout ratio
58%
After 10 yrs · $10,000 · DRIP
Portfolio value
$39.9K
Annual income
$1,154.43
Full ABBV calculator →

Portfolio growth — EES vs ABBV

📍 ABBV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodEESABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, EES + ABBV cover 4 of 12 monthsgood coverage

Jan
ABBV
Feb
Mar
Apr
ABBV
May
Jun
Jul
ABBV
Aug
Sep
Oct
ABBV
Nov
Dec
EES pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

EES
Annual income on $10K today (after 15% tax)
$104.77/yr
After 10yr DRIP, annual income (after tax)
$113.48/yr
ABBV
Annual income on $10K today (after 15% tax)
$312.02/yr
After 10yr DRIP, annual income (after tax)
$981.27/yr
At 15% tax rate, ABBV beats the other by $867.78/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of EES + ABBV for your $10,000?

EES: 50%ABBV: 50%
100% ABBV50/50100% EES
Portfolio after 10yr
$30.7K
Annual income
$643.98/yr
Blended yield
2.10%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

EES
No analyst data
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+51.7% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

EES buys
0
ABBV buys
0
No recent congressional trades found for EES or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricEESABBV
Forward yield1.23%3.67%
Annual dividend / share$0.71$6.20
Payout ratio50%58%
1-year div growth0%4.7%
5-year div CAGR0%8.9%
Portfolio after 10y$21.4K$39.9K
Annual income after 10y$133.51$1,154.43
Total dividends collected$1.3K$7.2K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: EES vs ABBV ($10,000, DRIP)

YearEES PortfolioEES Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$10,823$123.25$11,520$399.75$697.00ABBV
2$11,706$124.67$13,261$450.98$1.6KABBV
3$12,651$126.02$15,255$508.41$2.6KABBV
4$13,664$127.28$17,536$572.74$3.9KABBV
5$14,749$128.48$20,145$644.78$5.4KABBV
6$15,911$129.61$23,126$725.38$7.2KABBV
7$17,155$130.67$26,532$815.52$9.4KABBV
8$18,488$131.68$30,420$916.26$11.9KABBV
9$19,915$132.62$34,855$1,028.80$14.9KABBV
10$21,442$133.51$39,914$1,154.43$18.5KABBV

EES vs ABBV: Complete Analysis 2026

EESStock

Under normal circumstances, at least 95% of the fund's total assets (exclusive of collateral held from securities lending) will be invested in component securities of the index and investments that have economic characteristics that are substantially identical to the economic characteristics of such component securities. The index is a fundamentally weighted index that is comprised of earnings-generating companies within the small-capitalization segment of the U.S. stock market. The fund is non-diversified.

Full EES Calculator →

ABBVHealthcare

AbbVie is a pharmaceutical giant best known for Humira and newer blockbusters Skyrizi and Rinvoq. A Dividend Aristocrat with 52+ years of consecutive dividend increases. Strong free cash flow generation supports its above-average yield. The company's diversified pipeline reduces dependence on any single drug.

Full ABBV Calculator →
📬

Get this EES vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

EES vs SCHDEES vs JEPIEES vs OEES vs KOEES vs MAINEES vs JNJEES vs MRKEES vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.